Recently, more and more molecular markers have been identified that can be used for better diagnosis, treatment and prognostic assessment of glioma patients., including mutations in isocitrate dehydrogenase (IDH), O6-methylguanine-DNA methyltransferase (MGMT) methylation, deletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p/19q), and various signaling pathways involved in tumor suppression, proliferation, and migration (Wang et al., 2013; Molenaar et al., 2014; Zeng et al., 2015). The gene discussed is MGMT; the disease is neoplasm.